Tarsus Pharmaceuticals Inc
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
TARS$73.83+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and par value amounts)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $175,787 | $94,819 |
| Marketable securities | 232,129 | 196,557 |
| Accounts receivable, net | 62,426 | 46,760 |
| Inventory | 2,705 | 2,620 |
| Other receivables | 1,727 | 1,299 |
| Prepaid expenses | 5,999 | 14,650 |
| Total current assets | 480,773 | 356,705 |
| Restricted cash, non-current | 2,563 | 2,562 |
| Inventory, non-current | 2,532 | 2,533 |
| Property and equipment, net | 2,787 | 2,314 |
| Intangible assets, net | 8,086 | 8,326 |
| Operating lease right-of-use assets | 393 | 552 |
| Long-term investments | 3,000 | 3,000 |
| Other assets | 616 | 999 |
| Total assets | $500,750 | $376,991 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and other accrued liabilities | $76,375 | $64,789 |
| Accrued payroll and benefits | 9,933 | 15,823 |
| Total current liabilities | 86,308 | 80,612 |
| Long-term debt, net | 71,984 | 71,845 |
| Total liabilities | 158,292 | 152,457 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 41,995,537 shares issued and outstanding at March 31, 2025 (unaudited); 38,349,826 shares issued and outstanding at December 31, 2024 | 6 | 6 |
| Additional paid-in capital | 727,697 | 584,559 |
| Accumulated other comprehensive income (loss) | 85 | 179 |
| Accumulated deficit | (385,330) | (360,210) |
| Total stockholders’ equity | 342,458 | 224,534 |
| Total liabilities and stockholders’ equity | $500,750 | $376,991 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.